<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279188</url>
  </required_header>
  <id_info>
    <org_study_id>AF 3.2.92.45, AMPUL</org_study_id>
    <secondary_id>AF 3.2.92.45</secondary_id>
    <nct_id>NCT00279188</nct_id>
  </id_info>
  <brief_title>Asthma Management Project University Leiden</brief_title>
  <official_title>Asthma Management Project University Leiden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Netherlands Asthma Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <brief_summary>
    <textblock>
      The long-term course of asthma shows variable outcome with regard to the incidence of&#xD;
      exacerbations and the decline of lung function over time. The present study aimed:&#xD;
&#xD;
        1. to investigate whether asthma management additionally guided by the degree of bronchial&#xD;
           hyperresponsiveness leads to a better outcome&#xD;
&#xD;
        2. to examine the predictors among clinical and inflammatory disease markers of the&#xD;
           long-term decline in lung function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is associated with a specific inflamma¬tory state of the airways. Assuming that the&#xD;
      degree of airway inflammation is a determinant for the long-term disease outcome, it follows&#xD;
      that, asthma therapy should be aimed at maximal reduction of airway inflammation, in addition&#xD;
      to reducing symptoms. However, according to current guidelines, therapy should only be&#xD;
      directed to the clinical severity of the disease. There is increasing evidence that bronchial&#xD;
      hyper¬respon¬siveness can be used as a non-invasive reflection of airway inflamma¬tion [29].&#xD;
      However, it is still unknown whether bronchial responsiveness provides relevant additional&#xD;
      information for adjusting therapy during follow-up of patients with asthma. Therefore, in&#xD;
      this study we will:&#xD;
&#xD;
        1. compare the disease outcome in two parallel groups of patients with asthma, receiving&#xD;
           therapy aimed at either clinical severity only, or therapy aimed at both clinical&#xD;
           severity, and bronchial hyper¬responsiveness to methacho¬li¬ne. The outcome will be&#xD;
           assessed at three levels. First, the severity, second, lung function and bronchial&#xD;
           responsive¬ness, and third, humoral, cellular, and histological indices of airway&#xD;
           inflamma¬tion. To that end we will assess symptoms, lung function, bronchial&#xD;
           respon¬siveness, and immunological parameters in blood, every three months. Furthermore,&#xD;
           a bronchos¬copy with a bronchoalveolar lavage and bronchial biopsy will be carried out&#xD;
           to provide for material for immunologic and pathologic anatomical examination, at the&#xD;
           beginning and at the end of the study.&#xD;
&#xD;
        2. analyse the predictors among clinical- and inflammatory parameters of exacerbations and&#xD;
           long-term decline in lung function during long-term follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1992</start_date>
  <completion_date>September 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exacerbations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-bronchodilator FEV1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchial hyperrsponsiveness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway inflammationn in bronchial biopsies</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Guiding therapy by bronchial hyperrsponsiveness</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Asthma based on GINA guidelines (www.ginasthma.org)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  oral steroids&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Sterk, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>NL-2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.lumc.nl</url>
    <description>Leiden University Medical Center</description>
  </link>
  <reference>
    <citation>van Rensen EL, Sont JK, Evertse CE, Willems LN, Mauad T, Hiemstra PS, Sterk PJ; AMPUL Study Group. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med. 2005 Oct 1;172(7):837-41. Epub 2005 Aug 4.</citation>
    <PMID>16085937</PMID>
  </reference>
  <reference>
    <citation>Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1043-51.</citation>
    <PMID>10194144</PMID>
  </reference>
  <verification_date>September 2004</verification_date>
  <study_first_submitted>January 17, 2006</study_first_submitted>
  <study_first_submitted_qc>January 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2006</study_first_posted>
  <last_update_submitted>January 17, 2006</last_update_submitted>
  <last_update_submitted_qc>January 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2006</last_update_posted>
  <keyword>Bronchial hyperresponsiveness</keyword>
  <keyword>Atopy</keyword>
  <keyword>Inhaled steroids</keyword>
  <keyword>Exacerbations</keyword>
  <keyword>Lung function decline</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

